Stefan Andreas Abele, Chief Technical Ops Officer of Pharvaris N.V. (NASDAQ:PHVS), filed a Form 4 on September 16, 2026, reporting a series of transactions in common stock and stock options dated September 15, 2026.
Key Highlights
- Option exercise: Abele exercised a stock option covering 45,000 shares of common stock at an exercise price of $16.40 per share via a transaction coded "M."
- Cashless sale (options-related): 45,000 shares were sold at a weighted average price of $38.1375, with individual sale prices ranging from $38.00 to $38.35.
- Additional share sale: 1,400 shares acquired upon vesting of restricted stock units were sold at a weighted average price of $39.2411, with individual prices ranging from $39.2150 to $39.27.
- Remaining common stock: Following all reported transactions, Abele directly held 39,068 shares of common stock.
- Remaining derivative securities: Abele retained 44,500 stock options (right to buy) with an exercise price of $16.40 and an expiration date of November 15, 2033.
- Vesting schedule: According to the filing, 25% of the option vested on November 15, 2024, with the remaining shares vesting in 1/48 monthly installments thereafter.
Pharvaris Officer Reports Option Exercise and Share Sales on September 15, 2026
According to the Form 4 filed with the SEC, Stefan Andreas Abele, serving as Chief Technical Ops Officer of Pharvaris N.V. (NASDAQ:PHVS), executed three transactions on September 15, 2026. The first was the exercise of a stock option covering 45,000 shares of common stock at an exercise price of $16.40 per share, coded "M" in the filing. Prior to those disposals, Abele's direct beneficial ownership of common stock stood at 85,468 shares following that option exercise.
The filing discloses that 45,000 shares were then sold in connection with the cashless option exercise at a weighted average price of $38.1375 per share. The filing notes these sales occurred across multiple transactions with prices ranging from $38.00 to $38.35. Separately, 1,400 shares that had been acquired upon vesting of restricted stock units were sold at a weighted average price of $39.2411, across transactions with prices ranging from $39.2150 to $39.27 per share.
After all three transactions, the filing reports Abele directly held 39,068 shares of common stock. On the derivative securities side, the filing shows Abele retains 44,500 stock options with an exercise price of $16.40 and an expiration date of November 15, 2033, held directly. The Form 4 was signed by Marnus Nel as Attorney-in-Fact for Stefan Abele and dated September 16, 2026.
What Was Disclosed
Pharvaris N.V.'s Chief Technical Ops Officer reported the exercise of 45,000 stock options, the sale of 45,000 related shares and 1,400 RSU-vested shares on September 15, 2026, leaving direct holdings of 39,068 common shares and 44,500 remaining stock options.



Please wait processing your request...